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Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
Aims: The aim of this study was to determine if elas-
tin content in needle core native liver biopsies was
predictive of clinical outcome in patients with chronic
hepatitis C virus-related chronic liver disease.
Methods and results: Elastin contents in liver biopsies
were determined by image analysis, technically vali-
dated in an independent centre, and correlated with
outcome in patients with advanced (Ishak stage ≥5)
chronic hepatitis C virus-related chronic liver disease.
Elastin was robustly quantified in an operator-inde-
pendent and laboratory-independent manner, with
very strong correlation of elastin staining measured
with two methods of image classification (rs = 0.873,
P < 0.00001). Elastin content (but not absolute scar
content or Ishak stage) was predictive for future clin-
ical outcomes. In a cohort of patients without sus-
tained virological response, the median hepatic
elastin content was 3.4%, and 17 patients (57%)
progressed to a liver-related clinical outcome; 11 of
the 15 patients (73%) with a hepatic elastin content
of >3.4% progressed to a clinical outcome, as com-
pared with only six of 15 (40%) with an elastin con-
tent of <3.4%. The difference in time to outcome
was significant.
Conclusions: We describe a simple and reproducible
method for elastin quantification in liver biopsies that
provides potentially valuable prognostic information
to inform clinical management.
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Introduction
Although the safety of needle biopsy of the liver is
increasing,1 there remain non-zero mortality and
morbidity rates, even with image-guided procedures,2
and biopsy remains essential for the diagnosis and
assessment of liver disease.3 However, in contrast to
the use of biopsy material from other tissues,4
additional evaluation to yield prognostic, personalised
information is not undertaken.
Chronic liver disease (CLD) represents a significant
global health burden. In progressive liver injury, fibrotic
neomatrix production, coordinated by hepatic myofi-
broblasts, exceeds native matrix degradation by matrix
metalloproteinases (MMPs), resulting in progressive
scar accumulation. However, after cessation of injury
or treatment of the primary disease, the liver has the
capacity for profound recovery. Data from well-charac-
terised animal models5,6 and studies in human CLD7,8
have demonstrated the potential reversibility of hepatic
fibrosis. Moreover, histological regression of fibrosis is
associated with a reduction in portal hypertension and
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improved clinical outcomes.9–11 The factors limiting the
reversibility of fibrosis are less well understood, particu-
larly in human CLD. Such factors could be important in
predicting future decompensation events (e.g. variceal
bleeding and ascites) or persistent hepatocellular carci-
noma (HCC) risk,12,13 and in the selection of patients for
potential antifibrotic trials.
Elastin is an extracellular matrix (ECM) protein con-
ferring elastic recoil to tissues. It is extremely stable
in vivo, owing to cross-linking and extreme hydropho-
bicity. Elastin is only a minor ECM component in nor-
mal liver, but it is actively synthesised as its soluble
precursor, tropoelastin, by hepatic myofibroblasts in
human fibrotic liver.14 Covalent cross-linking of tropoe-
lastin monomers results in an insoluble, mature elastin
polymer that makes accumulated scar ECM more resis-
tant to degradation, limiting the reversibility of fibrosis.
Evidence for elastin turnover in vivo comes from stud-
ies showing elevated serum levels of MMP-mediated
elastin breakdown fragments15 and urinary concentra-
tions of markers of degradation of mature cross-linked
elastin (desmosine and isodesmosine) in patients with
cirrhosis.16 Furthermore, these urinary biomarkers cor-
related with liver fibrosis scores in biopsies from patients
with CLD secondary to hepatitis C virus (HCV) infection
and alcohol consumption. Elastin turnover has also
been studied longitudinally in liver biopsies from 21
patients with chronic viral hepatitis;17 this indicated
that deposition of elastic fibres occurred concomitantly
with the formation of thick collagen bands. This is con-
sistent with other studies showing that older scars in
liver biopsy specimens can be identified by their elastin
content.18–20 More recently, hepatic elastin content has
been shown to be associated with subsequent progres-
sion to the development of HCC in a cohort of patients
with advanced fibrosis related to HCV.21
We hypothesised that the elastin content of fibrotic
ECM in advanced CLD varies between individuals,
and that hepatic elastin content may predict the
occurrence of adverse clinical events. We have devel-
oped a robust, reproducible method that utilises exist-
ing biopsy material to quantify hepatic elastin and
predict poor clinical outcome. Extracting additional
information from biopsy material also favourably
shifts the risk/benefit ratio of the procedure.
Materials and methods
P A T I E N T C O H O R T S
Trent HCV biopsies
The study cohort was derived from a single centre
(Nottingham) within the Trent Study of Patients with
Hepatitis C Virus Infection, a prospective observa-
tional study designed to follow the natural history of
HCV infection.22 Patients underwent liver biopsy as
part of routine clinical care, and consented for tissue
surplus to diagnostic purposes to be used for research.
Albumin–bilirubin scores were calculated to assess
the severity of liver dysfunction.23 The Trent HCV
study was approved by the regional ethics committee
(MREC 98/3/55).
To enrich the study for a future endpoint of clinical
outcomes, we selected patients who had both advanced
liver fibrosis and evidence of progressive disease. The
inclusion criteria for elastin evaluation were as follows:
active chronic HCV infection without a sustained viro-
logical response to therapy before or after biopsy;
biopsy performed before 2011, allowing time for clini-
cal outcomes to develop; biopsy assessed as Ishak stage
≥5 by an independent histopathologist blinded to other
clinical information; adequate tissue remaining in the
block available for elastin immunohistochemistry; and
no clinical outcome before biopsy.
Lothian explant study samples
For technical validation of elastin staining by the use of
samples from a different centre stained in an indepen-
dent laboratory, non-hilar sections from human
explant liver were obtained by application to the Loth-
ian NRS Human Annotated Bioresource (ethical
review number 15/ES/0094). Samples were of mixed
aetiology: seven cirrhotic (two alcohol-related liver dis-
ease, one primary sclerosing cholangitis, two primary
biliary cholangitis, one HCV, and one cryptogenic) and
one non-fibrotic (acute liver failure without fibrosis,
attributed to drug-induced liver injury).
H I S T O P A T H O L O G Y
Quantitative histology and digital image analysis using
the Trent HCV study biopsies
Four-micrometre sections from biopsies were stained
with picrosirius red (PSR), as described previously,5
for Ishak24 and Laennec25 scoring and quantification
of liver fibrosis.
To identify elastin, 4-lm sections were stained with
a commercially available rabbit IgG polyclonal anti-
body against elastin (ab21610; Abcam, Cambridge,
UK). The primary antibody was used at a dilution of
1:200 (15 min) on Leica Bond Max stainers after
antigen unmasking with Epitope retrieval solution 2
(EDTA-based pH 9.0, AR9640; Leica Microsystems,
Milton Keynes, UK). Staining was visualised with the
Bond Polymer Refine Detection kit (DS9800; Leica
Microsystems).
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For biopsies from the Trent HCV study cohort,
whole-slide images of PSR-stained sections and sec-
tions stained for elastin were acquired at 920 magni-
fication (NanoZoomer; Hamamatsu Photonics,
Shizuoka, Japan) and split manually into smaller tiles.
Post-acquisition analysis was performed with an
IMAGEJ
26 plugin created in-house, employing statistical
colour modelling to threshold images.27 No manual
curation or masking of structures was undertaken
before analysis.
Quantification of elastin immunopositivity was
repeated independently at a second centre with the
same raw whole-slide images. Images were split by
the use of NDPISPLIT28 into tiles of 95 magnification
before the application of a classifier that had been
generated by a specialist liver histopathologist using
the machine learning WEKA plugin in FIJI.29,30 All
analysis was undertaken blind to all clinical and his-
tological data.
Lothian liver explant samples
Additional work was undertaken at a second UK liver
centre with alternative non-automated staining proto-
cols. Four-micrometre sections of explanted cirrhotic
liver were stained both with (Verhoeff’s) Elastic van
Gieson (EVG) and the same anti-elastin primary anti-
body at the same dilution (1:200). Antigen retrieval
was undertaken by 15 min of microwaving in EDTA
pH 9.0 solution; the primary antibody was applied
for 1 h at room temperature; and signal amplification
was performed with a VECTASTAIN ABC HRP kit
(Vector Laboratories, Peterborough, UK), according to
the manufacturer’s instructions.
C L I N I C A L O U T C O M E S
A clinical outcome was defined as the first event
recorded of: (i) ascites requiring treatment; (ii) vari-
ceal bleeding; (iii) overt hepatic encephalopathy; (iv)
orthotopic liver transplantation; (v) liver-related
death; or (vi) development of HCC. Patients present-
ing with new-onset ascites but diagnosed with HCC
during investigation were recorded as having HCC.
Data collection ceased in 2014, and none of the
patients received treatment with direct-acting antivi-
ral agents. Data from hospital records were supple-
mented with data from the Office of National
Statistics on cause of death and cancer registrations.
Patients who did not reach a clinical outcome during
the follow-up period were censored at either the time
when they were last seen alive without evidence of a
liver-related clinical outcome, or the time of non-
liver-related death.
S T A T I S T I C S
All data were tested for normality with the Shapiro–
Wilk test and by examination of Q–Q plots, allowing
appropriate parametric or non-parametric tests to be
used. Parametric data are described as mean  stan-
dard deviation; non-parametric data are presented as
median with interquartile range (IQR). Spearman’s
correlation coefficient (rs) was used to measure the
strength and direction of association between two
ranked non-parametric variables. Bland–Altman (BA)
plots and intraclass correlation (ICC) coefficients were
used for additional comparison of elastin quantifica-
tion methods. The difference in time to outcomes was
assessed with the log-rank (chi-square) test. Cox
regression analysis was used to determine factors
associated with time to clinical outcomes. Statistical
analysis was performed with IBM SPSS STATISTICS 22
and the RSTUDIO implementation of R.31 A P-value of
<0.05 was considered to be statistically significant.
Results
D E V E L O P M E N T , T E C H N I C A L V A L I D A T I O N A N D
R E P R O D U C I B I L I T Y O F E L A S T I N S T A I N I N G
Elastin and PSR contents in the Trent HCV study
samples were quantified with the previously described
IMAGEJ plugin27 (Figure 1A,B); patient characteristics
of the cohort are shown in Table 1. The median elas-
tin content was higher in biopsies classified as Ishak
stage 6 than in those classified as Ishak stage 5 (Fig-
ure 1C), although the difference in median content
(independent samples median test, P = 0.27) or distri-
bution (Mann–Whitney U-test, P = 0.064) was not
significant. There was a wide range of elastin content
in biopsies from both Ishak categories: Ishak stage 5,
median content of 2.51% (IQR 2.07–4.36; minimum
of 1.44, maximum of 8.05); and Ishak stage 6, med-
ian content of 3.61% (IQR 2.65–4.52; minimum of
1.69, maximum of 11.19).
The difference in PSR content between Ishak stages
5 and 6 was significant (Figure 1D;
18.80%  11.52% versus 30.57%  11.24%; Welch
two-sample t-test, t = –3.46, degrees of free-
dom = 42.46, P = 0.0012). There was a statistically
significant, moderate positive correlation between
elastin content and collagen content (Figure 1E;
rs = 0.58, P = 0.000047).
For technical validation of elastin staining and
quantification, elastin was quantified from the same
whole-slide images by an independent observer blind
to all data using an alternative method of image
© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
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Figure 1. Quantification of elastin and fibrosis in biopsies of advanced (Ishak stage ≥5) hepatitis C virus infection. Biopsies from patients with
chronic hepatitis C virus infections and advanced stage (Ishak stage ≥5) were stained with an antibody against elastin or with picrosirius
red (PSR); representative whole-slide images of a single case are shown (A and B, respectively; main scale bars 5 mm, inset 100 lm). Elastin
and PSR contents were quantified by image analysis; there was no significant difference in elastin content between Ishak stages 5 and 6 (C,
2.51%, interquartile range (IQR) 2.07–4.36, and 3.61%, IQR 2.65–4.52, respectively; independent samples median test, P = 0.27] but there
was a significant difference in PSR content between Ishak stages 5 and 6 (D, 18.80%  11.52% and 30.57%  11.24%, respectively,
Welch two-sample t-test, P = 0.0012). There was a moderate positive correlation between elastin content and collagen content (E, rs = 0.58,
P = 0.000047, regression line from fitted linear model and 95% confidence intervals).
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classification (WEKA). There was very strong rank cor-
relation of elastin quantified with both methods (Fig-
ure 2A,B; rs = 0.87, P < 0.00001). However, as
expected from the raw values, absolute agreement
between methods showed systematic proportional dif-
ferences on the BA plot (Figure S1), and poor agree-
ment by ICC [one-way; ICC(1) = 0.098, P = 0.258].
To confirm the reproducibility of immunohisto-
chemical detection of elastin in fibrotic liver and
supportive tinctorial staining, sections from native
explant hepatectomies, from a spectrum of primary
aetiologies, and from a single non-fibrotic partial
hepatectomy were obtained at a second UK liver
centre and stained in a different laboratory with a
separate batch of the same primary antibody. A
manual protocol that did not require an automated
stainer, with alternative signal amplification, was
used. In parallel, tinctorial identification of elastin
by EVG staining was undertaken on sections from
the same block (Figure 2C) to confirm elastin iden-
tification.
Elastin was evident and quantified in fibrous scars
of cirrhotic explants (median cirrhotic elastin content
of 4.7%, IQR 2.2–9.3; non-fibrotic elastin content of
0.2%; Figure S2), with clear histological spatial
equivalence between elastin immunopositivity and
dark blue/black elastin tinctorial staining by EVG.
Staining intensity was reduced as compared with
automated staining. This demonstrated broad aetiol-
ogy-agnostic relevance and the interlaboratory appli-
cability of antibody-based image analysis to quantify
elastin.
E L A S T I N C O N T E N T C A N P R E D I C T A D V E R S E
C L I N I C A L O U T C O M E I N P A T I E N T S W I T H
A D V A N C E D F I B R O S I S
Seventeen patients (57%) progressed to a liver-related
clinical outcome in the follow-up period after liver
biopsy (median follow-up of 5.8 years; IQR 3.0–8.3).
Recorded outcomes were: ascites (n = 8), variceal
bleeding (n = 1), liver-related death (n = 2), and HCC
(n = 5); one patient presented with ascites and
Table 1. Clinical, biochemical and histological characteris-
tics of patients of the Trent HCV study cohort
Variable Median IQR Number
Age (years) 49 42–54 30
Male gender 23 (77%)
BMI (kg/m2) 27 25–30 27
Estimated duration
from infection to
biopsy (years)
28 20–31 27
Past heavy alcohol use 17 (57%)
Heavy alcohol use
(>50 units/week)
9 (30%)
HCV genotype
1 10 (33%)
2 0
3 17 (57%)
4 1 (3%)
Albumin (g/l) 36 38–40 27
Bilirubin (lmol/ml) 12 9–16 29
ALP (u/l) 113 86–220 29
GGT (u/l) 166 82–339 29
ALT (u/l) 127 85–201 29
Ishak stage 5 16 (53%)
Ishak grade
0–6 13 (43%)
7–12 16 (53%)
13–18 1 (3%)
Laennec stage
3 3 (10%)
4A 3 (10%)
4B 10 (33%)
4C 14 (47%)
PSR (collagen) (%) 22.8 15.6–29.9 30
Table 1. (Continued)
Variable Median IQR Number
Elastin (%) 3.4 2.2–4.7 30
Biopsy length (mm) 14.5 11.8–18.0
Number of portal
tracts
15 13–20
ALBI score 2.6 2.77 to 2.39 27
ALBI, albumin–bilirubin; ALP, alkaline phosphatase; ALT, alanine
transaminase; BMI, body mass index; GGT, c-glutamyl transferase;
HCV, hepatitis C virus; IQR, interquartile range; PSR, picrosirius red.
© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
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Figure 2. Independent validation of immunohistochemical elastin quantification and technical validation. Elastin contents in original whole-
slide images were independently quantified with an alternative machine learning-based approach (A) to classify images into elastin-immuno-
positive (lilac) and elastin-immunonegative (green) tissue or blank (red) pixels. There was very strong rank correlation of elastin quantified
with both methods (B, rs = 0.87, P < 0.00001). Explant liver from a second liver centre from cases with a spectrum of primary aetiologies
was independently stained with a different batch of the same primary anti-elastin antibody by use of a non-automated protocol to demon-
strate centre-agnostic and disease-agnostic applicability (C, representative images); sections from the same blocks were also tinctorially
stained to identify elastin (Elastic van Gieson) and demonstrate spatial equivalence in areas of fibrosis and internal elastic lamina of arteries
as an internal positive control. Scale bars: 100 lm.
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encephalopathy simultaneously. None of the patients
underwent transplantation.
Factors associated with time to subsequent clinical
outcomes were determined (Table 2). On Cox regres-
sion analysis, only elastin content and alkaline phos-
phatase (ALP) were significant in univariate analysis;
Ishak stage and PSR (collagen) content were not
predictors of adverse outcome within this cohort. ALP
remained significant in multivariate analysis [ALP
hazard ratio 1.009, 95% confidence interval (CI)
1.0033–1.015, P = 0.0021; elastin hazard ratio
1.123, 95% CI 0.891–1.402, P = 0.306].
The median elastin content determined with the
primary quantification method for the cohort was
3.4% (IQR 2.2–4.7). Eleven of 15 patients (73%) with
greater than median elastin content progressed to a
clinical outcome, as compared with only six of 15
(40%) of those with elastin content below the group
median. The difference in time to outcomes was sig-
nificant (log rank: chi-square test 3.98; P = 0.046;
Figure 3A). Elastin content quantified by WEKA classifi-
cation (median 7.5, IQR 5.9–14.4) was also predic-
tive of clinical outcome; a calculated optimum cut-off
value of 6.2% also gave a significant difference in
time to outcome (log rank: chi-square test 4.6;
P = 0.0312; Figure 3B).
We performed a subgroup analysis to ascertain
whether elastin was a predictor of HCC as a single
outcome in our cohort. Only five patients (17%)
developed HCC during the follow-up period. Elastin
content was not statistically associated with the
development of HCC [Cox regression: exp(B) 1.00
(0.61–1.62); P = 0.99].
Discussion
In this study, we have developed a method to obtain
clinically useful prognostic information from existing
liver biopsy material, using an anti-elastin primary anti-
body and digital image analysis to detect and quantify
elastin content in advanced CLD, and confirmed with
independent classification methods. Histological equiv-
alence in identification of elastin by both immunohisto-
chemistry and a well-characterized tinctorial stain
(EVG) was demonstrated. The use of an antibody to
identify elastin, based on initial animal studies by the
Edinburgh group,18,32 has the advantage of conferring
the specificity that may be needed in antifibrotic studies,
but the disadvantage of adding additional complexity
and cost as compared with tinctorial stains.
As a proof-of-concept, we chose a group of patients
with HCV infection and advanced CLD lacking a sus-
tained virological response to standard contempory
treatment (i.e. pegylated interferon and ribavirin).
This restricted cohort was chosen to allow the study
of patients with rapid fibrosis progression and the
highest rate of adverse clinical outcomes. A recent
study demonstrated that elastin content is associated
with HCC development21 in patients with advanced
Table 2. Predictors of liver-related clinical outcomes; elas-
tin content and serum alkaline phosphatase (ALP) are the
only significant predictors of a liver-related clinical event, as
determined by univariate Cox regression analysis
Variable
Exp
(B) 95% CI
P-
value
Age (years) 1.059 0.989–1.134 0.100
Male gender 0.405 0.137–1.198 0.103
BMI (kg/m2) 1.093 0.961–1.245 0.177
Estimated duration from infection
to biopsy (years)
1.011 0.955–1.071 0.704
Past heavy alcohol use 1.371 0.464–4.049 0.568
Heavy alcohol use (>50 units/
week)
1.980 0.707–5.544 0.194
Genotype* 1.889 0.588–6.070 0.286
Albumin (g/l) 0.947 0.868–1.034 0.947
Bilirubin (lmol/ml) 1.031 0.960–1.107 0.404
ALP (u/l) 1.010 1.004–1.015 0.001
GGT (u/l) 1.001 0.999–1.003 0.279
ALT (u/l) 0.994 0.987–1.001 0.088
Ishak stage† 1.307 0.500–3.415 0.584
Laennec stage 3 (reference)
4A 0.490 0.030–7.961 0.616
4B 0.661 0.068–6.399 0.721
4C 2.058 0.265–16.005 0.490
Ishak grade, 0–6 versus 7–18 0.890 0.334–2.372 0.816
PSR (collagen) (%) 1.010 0.947–1.078 0.758
Elastin (%) 1.226 1.007–1.493 0.042
ALBI score 1.836 0.759–4.439 0.178
ALBI, albumin–bilirubin; ALT, alanine transaminase; BMI, body
mass index; CI, confidence interval; GGT, c-glutamyl transferase;
PSR, picrosirius red.
*Genotype 1 used as reference; analysis performed with compar-
ison of only genotypes 1 and 3.
†Ishak stage 5 used as reference standard.
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fibrosis. However, this was over a limited follow-up
period, and elastin as a predictor of decompensated
disease was not evaluated. We demonstrated signifi-
cant variation in elastin content in patients with
advanced CLD, and showed that elastin content can
be used as a tissue biomarker of adverse liver-related
outcomes. In contrast, neither Ishak stage nor PSR
(collagen) content predicted outcome in this cohort.
Liver biopsy remains an important clinical diagnos-
tic tool,3 but there is a clear obligation to extract as
much information from biopsy material as possible,
given the associated risks.1 The data provide encour-
agement to examine elastin in large, prospective
cohorts of advanced liver fibrosis patients with con-
tinuing liver injury. The demonstration of elastin in
different aetiologies of human disease suggests its
potential utility across all CLDs, but this requires
evaluation in disease-specific cohorts.
Staging of fibrosis with available ordinal scoring
systems is subject to considerable observer variability
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Figure 3. Elastin content functions as a tissue biomarker predictive of adverse liver-related events. A, Patients whose liver biopsies had elas-
tin content greater than the median (3.4%) according to primary classification more rapidly developed an adverse liver-related event than
those with biopsies whose elastin content was below this value; the difference in time to outcomes was significant (log rank: chi-square
3.98; P = 0.046). B, WEKA quantification indicated that biopsies with elastin content greater than the optimum calculated cut-off (6.2%)
more rapidly developed an adverse liver-related event than those with elastin content below this value; the difference in time to outcomes
was significant (log rank: chi-square 4.60; P = 0.0312).
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and generates crude ordinal data, indicating a need
for alternative methods of evaluation. Quantification
of fibrosis from biopsy material by the use of PSR-
stained sections addresses some of these problems,
but is not routinely undertaken in clinical practice. In
our study, establishment of a laboratory-specific stan-
dard allowed elastin content to be used as a tissue
biomarker predicting individual outcome from the
clinically indicated biopsy with minimal operator
input once standards had been established. With min-
imal cost and from a standard, clinically indicated
liver biopsy, quantification of elastin could be incor-
porated as part of more nuanced histological assess-
ment, e.g. stratifying patients who are unlikely to
benefit from putative antifibrotic therapy, or identify-
ing those requiring earlier referral for assessment for
liver transplantation. The ability to obtain this infor-
mation from whole-slide images, which can be cen-
trally verified and easily accessed, is of additional
value to clinical trials wishing to ensure that appro-
priate patients are included for investigation of novel
therapies.
The resistance of hepatic elastin to degradation
suggests that elastin content may influence the bal-
ance of fibrogenesis and reversibility in favour of scar
accumulation. Progressive scar formation with conse-
quent bridging of vascular structures leads to portal
hypertension. The non-HCC adverse liver-related out-
comes in this proof-of-concept study are related to
portal hypertension. Increased hepatic elastin content
may be a consequence of aberrant hepatic blood flow
and sinusoidal pressure; in the context of liver injury,
it has been suggested that elastin is deposited by por-
tal fibroblasts to limit damage caused by increased
biliary ductal pressure33 and that elastin deposition is
a result of tensile and shearing effects.34 It is also
recognised that a strained ECM leads to greater pro-
duction of fibrotic glycoproteins than a relaxed
ECM.35–37 Given the focus on predicting clinical out-
comes in advanced CLD, the role of elastin in home-
ostasis or during earlier stages of fibrogenesis has not
been examined.
This was an initial proof-of-concept study, and
therefore has inherent limitations. A single-aetiology
cohort has been studied; there is evidence that matrix
composition or amount may vary between diseases,38
so further work with additional cohorts of alternative
aetiologies and similarly prolonged follow-up is
required. The Cox regression analysis should be inter-
preted cautiously, given that the size of the pilot
cohort studied meant that recognised prognostic fac-
tors were not identified as significant by univariate
analysis. Additionally, it is clear that interlaboratory
differences in staining protocols and performance, as
demonstrated by the differences between manual and
automated staining in our study, mean that prescrip-
tive application of the cut-off value derived from this
study is inappropriate, and further work to allow lab-
oratory protocol harmonisation would be required
before routine application in practice. Quantifying
elastin from EVG-stained sections that are more read-
ily and reproducibly available is an obvious means of
minimising interlaboratory staining variation in order
to develop a more broadly applicable tool.
Elastin accumulates in fibrotic livers regardless of
the underlying aetiology, and is a key determinant of
irreversibility; its presence may predict the develop-
ment of clinical outcomes independently of collagen
fibres. Hepatic elastin quantification should be evalu-
ated further in larger studies to establish its potential
role in clinical decision-making and the selection of
patients for therapeutic trials.
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